Clinical Benefit From Immune Checkpoint Blockade in Sclerosing Epithelioid Fibrosarcoma: A Translocation-Associated Sarcoma

Doshi, S. D., Oza, J., Remotti, H., Remotti, F., Moy, M. P., Schwartz, G. K., & Ingham, M. (2021). Clinical Benefit From Immune Checkpoint Blockade in Sclerosing Epithelioid Fibrosarcoma: A Translocation-Associated Sarcoma. JCO Precision Oncology, 5, 1–5. https://doi.org/10.1200/po.20.00201
Authors:
Sahil D Doshi
Jay Oza
Helen Remotti
Fabrizio Remotti
Matthew P Moy
Gary K Schwartz
Matthew Ingham
Affiliated Authors:
Sahil D Doshi
Jay Oza
Helen Remotti
Fabrizio Remotti
Matthew P Moy
Gary K Schwartz
Matthew Ingham
Columbia Affiliation:
Subjects:
Fibrosarcoma (MeSH)
Immune Checkpoint Inhibitors (MeSH)
Myxosarcoma (MeSH)
elink
Publication Type:
Article
Unique ID:
10.1200/po.20.00201
PMID:
34994591
DOI:
10.1200/po.20.00201
Journal:
JCO Precision Oncology
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: